Location:
UNIVERSITY CLUB AUDITORIUM, University Club Western Australia.

8:00am – 9:00am     Poster Viewing 
9:00am – 9:45am     Plenary Speech: Professor Jin-Moo Lee MD, PhD 
                   (Washington University School of Medicine, Washington, USA)

 Jin-Moo Lee, MD, PhD. 

Andrew B. & Gretchen P. Jones Professor 

Chairman of Neurology

Neurologist in Chief, Barnes-Jewish Hospital
Title of Speech: White Matter Hyperintensity Spatial Patterns Reflect Distinct Cerebral Small Vessel Disease Pathologies

Jin-Moo Lee, MD, PhD, is the Andrew B. & Gretchen P. Jones Professor, Chairman of Neurology at Washington University School of Medicine, and Neurologist-in-Chief at Barnes-Jewish Hospital.  Dr. Lee is a physician-scientist and vascular neurologist, who has been studying the pathogenesis of stroke and Alzheimer’s disease, and the interface of these two diseases of the elderly.  His research spans the translational spectrum from cell and animal models of neurological diseases to clinical studies involving genetics and multimodal neuroimaging of patients.  Dr. Lee has published more than 200 research articles, chapters, reviews and editorials. In addition, he has been continuously funded by the NIH since 2000.  A major focus of Dr. Lee’s academic career has been research mentoring—he has mentored more than a dozen K-awardees—and has received several awards for mentorship, including the Sven Eliasson Award for Teaching Excellence and the Washington University Distinguish Faculty Mentorship Award.  In addition, he has received several awards for research excellence—most recently the Javits Neuroscience Investigator Award (R37 Merit Award).

Dr. Lee graduated from Yale College with a degree in Molecular Biophysics and Biochemistry, then attended Weill Cornell Medical College, earning an MD and PhD in neuroscience.  After completing residency training at the University of Pennsylvania, he completed a neurovascular fellowship at Washington University, where he subsequently joined the faculty in the Department of Neurology.
 

Coffee break (15 min)

10:00am – 11.05am    6. Theme (half session) Innovative animal model systems 
*Moderator:  Stephanie Rainey-Smith, PhD, Murdoch University, Western Australia

•  
• Learning dysfunction inAPP Dutch mice *Virtual

  – Sam Gandy, MD, PhD, Mount Sinai, New York, USA 

•  
• Novel rat models reveal molecular insights into the pathogenesis of CAA type-1 and CAA type-2. *Virtual

  – William van Nostrand, PhD, The University of Rhode Island, Kingston, USA

Selected Oral Abstracts
#1: A. Bonaterra-Pastra.  *Virtual

#2: J. Schrader

11:05am – 12:55pm    6b. Theme (half session) Fluid Biomarkers: Current and future Status 
*Moderator: Marcel Verbeek, PhD, Radboud University Medical Center, Nijmegen, Netherlands 

•  
• Plasma Biomarkers in AD 
    – Ralph Martins, PhD, Edith Cowan University, Joondalup, Australia
•  
• New experimental insights from CSF studies in humans

  – Marcel Verbeek, PhD, Radboud University Medical Center, Nijmegen, Netherlands  

•  
• Progressive white matter injury is independently associated with cerebral amyloid angiopathy and brain atrophy

  – Jasmeer Chhatwal, MD, PhD, Harvard Medical School, Boston, USA.  *Virtual

• Modern diagnostic perspectives in CAA-related syndromes

  – Andreas Charidimou, MD, Msc, PhD, Boston Medical Center, USA.*Virtual 

•  
• Selected Oral Abstracts 
• #1: E. van den Berg
  

  Conserved cerebrospinal fluid synaptic protein levels in CAA as opposed to AD

#2: E. van den Berg

#3:  B. Knepp.  *Virtual

12:55pm – 13:10pm Official Conference Closure 
  – Susanne Van Veluw, PhD, Harvard Medical School, Boston, USA
Winners Announcements (Students/ECR Posters and Presentations) 

1.10pm – 1.45pm    Lunch break/Poster Viewing

2:00pm – 4:30pm     Public Forum: CAA Community and Research:
*Moderator: Sanne van Rijn, MSC, Dorinda ‘t Hart, Msc,PhD, Maike Hoek 

2:00pm – 3:00pm:

The CAA conference  is the first time ever that researchers and patient advocates from three continents (Australia, USA and Europe) are together in one room to talk about TRACK DCAA and all other things Dutch-type CAA related. This provides us with the unique opportunity to inform (Australian) family members from DCAA families about the progress in our search for an intervention to stop or slow down the disease. The interactive public forum aims to facilitate an open discussion between the researchers working on the disease and the people they are doing it for.

1. Updates on Screening and Diagnosis, Treatment
2. Update on Track Dutch CAA for public (From Leiden to Perth)
3. Patient Advocates/Representatives: Sanne van Rijn (NL), Maike Hoek (NL), Dorinda ‘t Hart (AUS) 
4.  

2.00pm – 2.20pm. Welcome and update by Sanne van Rijn, patient advocate Dutch CAA patient Association
2.20pm – 2.40pm  Update on TRACK Dutch CAA and future trials
2.40pm – 3.00pm  Personal account 

3:00pm – 3:30pm  Coffee Break

3:30pm – 4:30pm  Q&A